论文部分内容阅读
本文评价静滴组织纤维蛋白溶酶原激活剂(Intravenous Tissue PlasminogenActivator;ITPA)和肝素(Heparin;HN)治疗急性大脑中动脉卒中(Acute MiddleCerebral Artery Stroke;AMCAS)的疗效与安全性。 32例经脑血管造影证实的严重大脑半球卒中综合征患者,在血管造影证实系AMCAS和(或)颅内颈内动脉闭塞后,立即予以ITPA(100 mg),同时注射HN5000单位,此后HN的用法为1000～1500U/小时,当头颅CT扫描证实脑出血时,即停用HN。ITPA治疗完毕后,立即行数字减影血管造影,12～24小时后再行经颅多普勒超声波检
This article evaluates the efficacy and safety of Intravenous Tissue Plasminogen Activator (ITPA) and Heparin (HN) in the treatment of Acute Middle Cerebral Artery Stroke (AMCAS). Thirty-two patients with severe hemisphere stroke syndrome confirmed by cerebral angiography were given ITPA (100 mg) immediately after angiography confirmed the presence of AMCAS and / or intracranial internal carotid artery occlusion and HN5000 units were injected simultaneously, after which HN Usage of 1000 ~ 1500U / hour, when the head CT scan confirmed cerebral hemorrhage, that disable the HN. ITPA treatment immediately after the digital subtraction angiography, 12 to 24 hours before transcranial Doppler ultrasound